Clinical Trial Update: Dasatinib for HIV-1 Reservoir Reduction [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating dasatinib to reduce HIV-1 reservoirs; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: NOT_YET_RECRUITING